MUMBAI (Reuters) – Sun Pharmaceutical Industries Ltd, which is to buy rival drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, said its unit Silverstreet Developers LLP had no role to play in the run-up in Ranbaxy shares ahead of the deal announcement in April.